Menu
About Us
Company Overview
Our Values
Board of Directors
Team
Scientific Advisers
Clinical Advisers
Corporate Directory
Corporate Governance
Pipeline
Clinical Trial
Investor Centre
Welcome
Investor Fact Sheet
ASX Announcements
Reports
Annual Reports
Half Yearly Reports
Quarterly Reports
Top 20 Shareholders
Research Reports
Shareholder Services
Investor FAQs
US Shareholders
Communication
In the News
Presentations
Posters
Publications
Contact Us
Contact Us
Email Alerts
Media
Recent Posts
Entitlement Offer to raise $4.27m
Proactive Interview with Dr Chris Burns
FDA clearance of Amplia's IND for pancreatic cancer trial in US
First patient dosed in phase 2a ACCENT trial
Investor Newsletter - December 2023
Approval from Korean regulator to initiate Phase 2 accent pancreatic cancer trial in Korea
Categories
Company News
Media
Uncategorized
Videos
02 Aug 2023
ACCENT Trial Recruitment Update
Read More
11 Jan 2023
Dose Escalation Approved in ACCENT Clinical Trial of AMP945
Read More
29 Jun 2022
The science of manufacturing, at scale
Read More
17 Mar 2022
Scientific rigour is in our DNA
Read More
07 Oct 2021
MEET THE TEAM | Dr John Lambert, CEO
Read More
04 Oct 2021
VIDEO | Science Advances paper discussed on Proactive
Read More
30 Sep 2021
VIDEO | Amplia featured on Channel 9 News
Read More
30 Sep 2021
BioMelbourne Network | Breakthrough research on pancreatic cancer
Read More
22 Sep 2021
Bioshares | Amplia Therapeutics to Start Two Phase II Studies in 2022
Read More
02 Jun 2021
Positive data sends Amplia Therapeutics nearly 50 per cent up
Read More
18 Mar 2021
Amplia Therapeutics signs agreement with Garvan Institute
Read More
17 Mar 2021
Amplia Therapeutics completes single-dose study of AMP945
Read More
14 Oct 2020
Joint Cancer Therapeutics CRC/AMPLIA Therapeutics Press Release
Read More
1